Safety and efficacy of inhaled human α-1 antitrypsin (AAT) in cystic fibrosis: a report of a phase II clinical study Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
The results of alpha-1 antitrypsine (AAT) phenotyping in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 260s Year: 2002
Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018
Phase I safety investigation of an aerosolized, recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 228s Year: 2004
Regional deposition of 99m Tc-labelled alpha-1 antitrypsin (AAT) in patients with alpha-1 antitrypsin deficiency and cystic fibrosis (CF) compared with healthy volunteers Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007
INTEGRIS-IPF: a 12-week, Phase 2a study evaluating the safety, tolerability and pharmacokinetics of PLN-74809 in participants with IPF Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
A well-designed/conducted study on alpha-1 antitrypsin epidemiology not quoted Source: Eur Respir J, 51 (3) 1702662; 10.1183/13993003.02662-2017 Year: 2018
Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
A high purity alpha-1 antitrypsin (AAT) from human plasma, TAL6004 Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Alpha-1 antitrypsin (AAT) and alpha-2 macroglobulin (AMG) levels according to the stages and histological types in lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1 -proteinase inhibitor in alpha1 -antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
A double-blind, placebo-controlled, study to assess the pharmacokinetics, safety and tolerability of multiple ascending intravenous doses of CAT 354, a recombinant human anti-IL13 antibody, in subjects with moderate asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Pilot study for detection of alpha-1 antitrypsin deficiency in a targeted Argentinean population Source: Eur Respir J 2005; 26: Suppl. 49, 59s Year: 2005
A phase 1B/2A study to evaluate the effect of aerosolized, recombinant alpha 1-antitrypsin (rAAT) on epithelial lining fluid (ELF) analytes in subjects with AAT deficiency Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021